A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Public ClinicalTrials.gov record NCT04508621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Study identification
- NCT ID
- NCT04508621
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 514 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2020 (Actual)
- Primary completion
- Nov 1, 2021 (Actual)
- Completion
- Nov 1, 2021 (Actual)
- Last update posted
- Dec 18, 2023
2020 – 2021
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tonix Clinical Site | Birmingham | Alabama | 35216 | — |
| Tonix Clinical Site | Phoenix | Arizona | 85016 | — |
| Tonix Clinical Site | Oceanside | California | 92056 | — |
| Tonix Clinical Site | San Diego | California | 92103 | — |
| Tonix Clinical Site | Santa Ana | California | 92705 | — |
| Tonix Clinical Site | Temecula | California | 32591 | — |
| Tonix Clinical Site | Cromwell | Connecticut | 06416 | — |
| Tonix Clinical Site | Fort Myers | Florida | 33912 | — |
| Tonix Clinical Site | Jacksonville | Florida | 32256 | — |
| Tonix Clinical Site | North Miami | Florida | 33161 | — |
| Tonix Clinical Site | Ocala | Florida | 34470 | — |
| Tonix Clinical Site | Orlando | Florida | 32801 | — |
| Tonix Clinical Site | Alpharetta | Georgia | 30022 | — |
| Tonix Clinical Site | Evansville | Indiana | 47714 | — |
| Tonix Clinical Site | West Des Moines | Iowa | 50265 | — |
| Tonix Clinical Site | Prairie Village | Kansas | 66208 | — |
| Tonix Clinical Site | New Orleans | Louisiana | 70115 | — |
| Tonix Clinical Site | Boston | Massachusetts | 02131 | — |
| Tonix Clinical Site | Albuquerque | New Mexico | 87109 | — |
| Tonix Clinical Site | Williamsville | New York | 14221 | — |
| Tonix Clinical Site | High Point | North Carolina | 27262 | — |
| Tonix Clinical Site | Raleigh | North Carolina | 27612 | — |
| Tonix Clinical Site | Cincinnati | Ohio | 45219 | — |
| Tonix Clinical Site | Dayton | Ohio | 45417 | — |
| Tonix Clinical Site | North Canton | Ohio | 44720 | — |
| Tonix Clinical Site | Oklahoma City | Oklahoma | 73112 | — |
| Tonix Clinical Site | Tulsa | Oklahoma | 74133 | — |
| Tonix Clinical Site | Portland | Oregon | 97210 | — |
| Tonix Clinical Site | Warwick | Rhode Island | 02886 | — |
| Tonix Clinical Site | Chattanooga | Tennessee | 37421 | — |
| Tonix Clinical Site | Memphis | Tennessee | 38119 | — |
| Tonix Clinical Site | Austin | Texas | 78737 | — |
| Tonix Clinical Site | Dallas | Texas | 75231 | — |
| Tonix Clinical Site | Salt Lake City | Utah | 84102 | — |
| Tonix Clinical Site | Charlottesville | Virginia | 22911 | — |
| Tonix Clinical Site | Kenosha | Wisconsin | 53144 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04508621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04508621 live on ClinicalTrials.gov.